AlphAIAlphAI — Financial news for AI agents
tickerreport.comMAY 303 min read$PRPO

Precipio (NASDAQ:PRPO) Stock Price Crosses Below 200

Precipio Inc. (NASDAQ:PRPO) shares fell below their 200-day moving average during Wednesday trading, trading as low as $23.44 and last at $23.55. The 200-day average is $25.08. The article cites recent analyst changes, including a downgrade to “hold” by Wall Street Zen and “sell” ratings from Weiss. Precipio reported May 14 quarterly EPS of ($0.81) on $6.71M revenue.

Original reporting
tickerreport.com
Published May 30, 2026, 12:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 30, 2026, 12:57 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Precipio (NASDAQ:PRPO) Stock Price Crosses Below 200 — source image
Source · tickerreport.com
Decision brief

The 30-second read

$PRPOBearishMed
01

Why it matters

Traders may treat the 200-day MA break as a trend-change signal, while the analyst-rating backdrop (mostly sell/hold) can limit dip-buying conviction.

02

Market read

Near-term trading focus is on whether PRPO can reclaim the $25.08 200-day MA after the breakdown.

03

What to watch

The piece cites prior earnings (May 14) but does not connect today’s move to a new catalyst; technical signals may dominate until fresh fundamentals arrive.

Relevance 7/10Novelty 6/10Timing: during Wednesday trading (intraday technical trigger)

Background

The article is a technical/positioning recap: PRPO crossed below its 200-day moving average ($25.08) and is trading near the low-$23s.

Company-level read

Ticker impact

$PRPOBearishMedium confidence
Context

Precipio shares broke below the 200-day moving average and traded down to $23.44, signaling renewed downside momentum.

Expected impact

Bias toward continued weakness/volatility until price reclaims the $25.08 200-day MA area.

Evidence & confidence

The article provides a concrete technical trigger (cross below 200-day MA) plus recent sell/hold rating mix; no new fundamental catalyst beyond referencing the prior earnings date.

Market effects

Sector

For clinical-stage diagnostics, technical weakness can amplify risk-off positioning even without new trial/approval news.

Regional

Primarily US small/mid-cap biotech sentiment; limited direct cross-region impact implied.

Global

Low—no global macro or cross-border transaction details provided.

Counterpoint

What could challenge this read

A move below the 200-day MA can be a short-term overreaction; if buyers defend near $23.4, a mean-reversion bounce toward $25 could follow.

Key entities

  • company
    Precipio, Inc.

    Clinical-stage diagnostics/medical technology company; subject of the stock-price technical break and rating updates.

Read at source← All news

Related articles

AUG 18
$PRPOMedAI 8/10

Precipio, Inc. Q2 2026 Earnings: Revenue Beats $7.02 Million Record

Precipio (NASDAQ: PRPO) reported Q2 2026 GAAP EPS of -$0.12 and a GAAP net loss of $0.219 million, alongside record net sales of $7.02 million, up about 24% year over year. Revenue beat the cited consensus $1.68 million. Product revenue rose to $0.906 million and adjusted EBITDA was $0.4 million. Cash at quarter-end was $3.08 million.

sci-tech-today.com4 min
AUG 14
$PRPOMed

Precipio, Inc. (PRPO): Results of Operations and Financial Condition

Precipio, Inc. (PRPO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Precipio Announces Q2-2026 Financial Results Revenue reaches quarterly record as Precipio returns to positive Adjusted EBITDA and strengthens cash position NEW HAVEN, CT, Globenewswire – (Aug 14, 2026) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PR

SEC EDGAR 8-K4 min
SEP 21
$TPBHigh

Why Turning Point Brands Stock Dived by 10% Today

Turning Point Brands (TPB) stock fell 10% on Monday due to unexpected CEO departure and a cut in EBITDA guidance. CEO Graham Purdy is leaving for personal reasons, and David Glazek will take over. The company reduced its full-year EBITDA forecast to $70M from $80M but maintained sales estimates for its oral tobacco products.

fool.com2 min
SEP 21
$METAMedAI 8/10

Meta's Muse gives Zuckerberg another shot at building a real platform

Meta's AI agent, Muse, became the top free app on the App Store, surpassing ChatGPT. Muse's success could attract developers and businesses, potentially creating a new platform. Meta's stock surged 11%, nearing a record high. The company opened Muse to developers, allowing businesses to integrate services. Shopify announced support for Muse, boosting its stock. Meta aims to position Muse as a primary online activity starting point, similar to Google Search or Apple's App Store.

businessinsider.com2 min
SEP 21
$NUAIHighAI 8/10

New Era Energy shares surge on 20-year power deal with Vistra for Texas data center project

New Era Energy & Digital (NUAI) secured a 20-year power deal with Vistra for its Texas data center, supplying 200-207 MW. Shares surged over 30% to $7.65. Power will come from Vistra's gas plant in Odessa. The agreement includes renewal options and Vistra's stake in the project. CEO Charlie Nelson highlighted reduced development risk. According to Vistra, demand for reliable power is growing in the U.S.

proactiveinvestors.com2 min